This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
GHRH agonists promote tissue regeneration, improve heart function, and help islet survival in diabetes models. GHRH antagonists show antitumor activity against lung, prostate, breast, and GI cancers with minimal toxicity in preclinical studies.
Why it matters
GHRH analogs may have therapeutic uses far beyond growth hormone regulation, spanning cancer, regenerative medicine, inflammation, and neurodegeneration.
The numbers in context
GHRH antagonist series MIA and AVR demonstrated antitumor activity in preclinical models of lung, prostate, breast, and gastrointestinal cancers.
How the study worked
Narrative review of preclinical and early clinical literature on GHRH agonists and antagonists across oncology, regenerative medicine, and metabolic disorders.
Who was studied
Preclinical models and early clinical data across oncology, regenerative medicine, and metabolic disorders
What this study cannot tell us
Review based mostly on preclinical data. Few human clinical trials. Long-term safety of GHRH analogs in these new indications is unknown.
Read the original research
The development of growth hormone-releasing hormone analogs: Therapeutic advances in cancer, regenerative medicine, and metabolic disorders.
Reviews in endocrine & metabolic disorders, 26(3), 385-396
Citation
Schally, Andrew V; Cai, Renzhi; Zhang, Xianyang; Sha, Wei; Wangpaichitr, Medhi. (2025). The development of growth hormone-releasing hormone analogs: Therapeutic advances in cancer, regenerative medicine, and metabolic disorders.. Reviews in endocrine & metabolic disorders, 26(3), 385-396. https://doi.org/10.1007/s11154-024-09929-2